Schema-Root.org logo

 

  cross-referenced news and research resources about

 Ariad Pharmaceuticals Inc.

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Mon. September 23, 2019

-
Among 8 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 0 have Buy rating, 1 Sell and 7 Hold. Therefore 0 are positive. Ariad Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Underweight” rating by Barclays Capital given on Tuesday, ...
William Blair reissued their outperform rating on shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) in a research note released on Friday. William Blair currently has a $15.00 price target on the pharmaceutical company's stock, up from their previous price target of $12.00.

Ariad Pharmaceuticals Inc. logo JMP Securities downgraded shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) from an outperform rating to a market perform rating in a research report released on Tuesday. JMP Securities currently has $9.37 target price on the pharmaceutical company's stock, up from ...
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)'s stock had its “outperform” rating reissued by stock analysts at Leerink Swann in a research report issued to clients and investors on Wednesday. They currently have a $20.00 price objective on the pharmaceutical company's stock. Leerink Swann's target price ...
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)'s stock had its “outperform” rating restated by Cowen and Company in a research report issued to clients and investors on Saturday. They currently have a $16.00 price target on the pharmaceutical company's stock, up from their previous price target of $10.00.
Cascadian Therapeutics (NASDAQ: CASC) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, valuation and institutional ...

The latest market report published by Credence Research, Inc. “Global Chronic Myeloid Leukemia (CML) Tretament Market – Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 – 2023,” the chronic myeloid leukemia (CML) treatment market was valued at USD 2,828.9 Mn in 2015, and ...
Among 8 analysts covering Ariad Pharmaceuticals (NASDAQ:ARIA), 0 have Buy rating, 1 Sell and 7 Hold. Therefore 0 are positive. Ariad Pharmaceuticals had 17 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was initiated by Barclays Capital with “Underweight” on Tuesday, ...
Companies profiled in this report include: Abbvie Inc., Adaptimmune, Aduro Biotech, Advantagene, Advaxis Immunotherapies, Amgen, Argos Therapeutics, Ariad Pharmaceuticals, Arog Pharmaceuticals, Aserta Pharmaceuticals, Astellas, Astrazeneca, Avax Technologies, Bavarian Nordic, Bayer Healthcare, ...
Clackson most recently served as president of research and development at ARIAD Pharmaceuticals until its acquisition by Takeda. He led the research and development team that discovered and brought to market two innovative targeted therapies for cancer and moved three additional medicines into ...
Takeda Pharmaceutical acquired a US oncology firm for about 5 billion dollars last year to speed up development of anti-cancer drugs. Ariad Pharmaceuticals is known for its leukemia and lung cancer medicines. America's Pfizer has also acquired Medivation with a promising cancer drug for about 14 ...
Auris Medical (NASDAQ: EARS) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings and analyst ...
Germano, Panayiotopoulos and Schlesinger have all been involved with other companies Denner's invested in, two of which Denner – a Carl Icahn protege – ultimately orchestrated the sale of: Bioverativ and Ariad Pharmaceuticals. "As a result of the rapid and significant evolution our business and the ...
Auris Medical (NASDAQ: EARS) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst ...
Early last year, Takeda paid $5.2 billion for Ariad Pharmaceuticals Inc. of Cambridge, which has a blood cancer drug on the market. Shire had drawn interest from other drug makers, too. In 2014, its chief executive, Flemming Ornskov, fought off a proposed takeover by AbbVie Inc. Last week, as Takeda ...
A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Ariad Pharmaceuticals Inc (NASDAQ: ARIA) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on April 26, 2018 and NASDAQ: ARIA investors should contact the ...
Some of the major companies operating in the global oncology drugs market are Amgen, Bayer Healthcare AG, CELGENE CORPORATION, GlaxoSmithKline, ARIAD Pharmaceuticals, Inc., Eli Lilly and Company, Novartis, Hoffmann-La Roche Ltd., AstraZeneca, Boehringer Ingelheim GmbH, Pfizer and ...

Ariad Pharmaceuticals logo Media stories about Ariad Pharmaceuticals (NASDAQ:ARIA) have trended somewhat positive this week, according to Accern. The research group rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks ...
Global Bile Duct Cancer Drug market Report offers decisive insights into the overall Bile Duct Cancer Drug industry along with the market dimensions and evaluation for the duration 2017 to 2022. The forenamed research study covers extensive analysis of various Bile Duct Cancer Drug industry segments ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 293 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Ariad Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, institutional ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Ariad Pharmaceuticals to related companies based on the strength of its dividends, earnings, valuation, ...
Ariad Pharmaceuticals logo Headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have been trending somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources.
Two Sigma Securities LLC purchased a new position in ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 40,608 shares of the pharmaceutical company's stock, valued at approximately ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Ariad Pharmaceuticals to related companies based on the strength of its risk, analyst recommendations, dividends, ...
Canada Pension Plan Investment Board increased its position in shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) by 284.2% during the third quarter, Holdings Channel reports. The firm owned 80,300 shares of the pharmaceutical company's stock after buying an additional 59,400 shares during the ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Ariad Pharmaceuticals to related businesses based on the strength of its earnings, analyst recommendations, ...
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) saw a significant decline in short interest in December. As of December 15th, there was short interest totalling 32,405,235 shares, a decline of 5.6% from the November 30th total of 34,332,623 shares. Currently, 17.3% of the shares of the company are short ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 289 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Ariad Pharmaceuticals to related companies based on the strength of its dividends, institutional ownership, profitability, ...
Ariad Pharmaceuticals (NASDAQ: ARIA) and Sucampo Pharmaceuticals (NASDAQ:SCMP) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, analyst recommendations, earnings, profitability, ...
Ariad Pharmaceuticals logo Media headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by analyzing more than 20 million news and blog sources.
Sucampo Pharmaceuticals (NASDAQ: SCMP) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, ...
Granite Point Capital Management L.P. boosted its stake in shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) by 6.2% during the third quarter, Holdings Channel reports. The institutional investor owned 457,415 shares of the pharmaceutical company's stock after buying an additional 26,525 shares ...
BlackRock Inc. increased its position in shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) by 6.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,154 shares of the pharmaceutical company's stock after ...
BlackRock Group LTD cut its stake in shares of ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) by 3.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 157,790 shares of the pharmaceutical company's stock ...
Ariad Pharmaceuticals logo News headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have been trending somewhat negative this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks ...
Ariad Pharmaceuticals logo Headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have been trending somewhat negative this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time.
Ariad Pharmaceuticals logo Press coverage about Ariad Pharmaceuticals (NASDAQ:ARIA) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) – Equities research analysts at Leerink Swann lowered their FY2018 EPS estimates for Ariad Pharmaceuticals in a report released on Tuesday. Leerink Swann analyst M. Schmidt now expects that the firm will post earnings of $0.00 per share for the year, down ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 290 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its competitors? We will compare Ariad Pharmaceuticals to similar businesses based on the strength of its analyst recommendations, institutional ownership, ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 290 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Ariad Pharmaceuticals to similar companies based on the strength of its valuation, earnings, analyst recommendations, ...
New York State Common Retirement Fund increased its position in ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) by 11.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,670 shares of the pharmaceutical ...
Ariad Pharmaceuticals (NASDAQ: ARIA) is one of 287 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it contrast to its peers? We will compare Ariad Pharmaceuticals to similar businesses based on the strength of its earnings, valuation, profitability, dividends, institutional ...
Heat Biologics (NASDAQ: HTBX) and Ariad Pharmaceuticals (NASDAQ:ARIA) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ...
Ariad Pharmaceuticals (NASDAQ: ARIA) and Heat Biologics (NASDAQ:HTBX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, earnings, profitability and institutional ...
Media stories about Ariad Pharmaceuticals (NASDAQ:ARIA) have been trending positive this week, according to Alpha One. Alpha One, a service of Accern, scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Alpha One ranks coverage of publicly-traded ...
Ariad Pharmaceuticals logo News stories about Ariad Pharmaceuticals (NASDAQ:ARIA) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than 20 million news and blog sources. Accern ...
Ariad Pharmaceuticals Inc.'s 2010 patent infringement suit against Eli Lilly, which is a crucial affirmation of the written description doctrine, is a ...
Ariad Pharmaceuticals logo News headlines about Ariad Pharmaceuticals (NASDAQ:ARIA) have trended somewhat positive recently, Accern ...
Ariad Pharmaceuticals Inc. logo JMP Securities reiterated their market perform rating on shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) ...
Ariad Pharmaceuticals logo Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)'s stock had its “outperform” rating reiterated by stock analysts at ...


 

news and opinion


 


 


 


 


schema-root.org

     ariad

pharmaceutical industry:
     allergan
     ariad
     astrazeneca
     baxter
     eli lilly
     glaxosmithkline
     merck
     mylan
     novartis
     pfizer
     products
     purdue pharma
     research
     takeda
     teva
     upjohn
     valeant